Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: This invention provides an isolated compound having the structure: or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.

Abstract: The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and/or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed.

Abstract: Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy.

Abstract: A pharmaceutical compound is provided. The pharmaceutical compound includes a first component as methrotrexate and a second component as cholesterol, wherein the first component is covalently conjugated to the second component having a structure represented by the following chemical formula (I): wherein ? carboxyl group of methrotrexate is conjugated to cholesterol using spermidine as a linker.

Abstract: A liquid composition contains a salicylate compound (e.g. aspirin), glycerin triacetate, saccharin. The salicylate compound is soluble in the composition, which is particularly suitable for oral, parenteral or pulmonary administration.

Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.

Abstract: The present invention provides a composition comprising a co-culture of at least two distinct bacterial families, having differing growth and/or proliferative conditions. In some embodiments, the composition comprises a plurality of bacterial genera with high similarity to microbial flora.

Abstract: A weight loss system is presented herein. In one embodiment, the weight loss system that accelerates weight loss in a subject eating a caloric restricted diet with a minimum daily protein intake of about 3 oz. and engaging in daily physical activity equivalent to about 5,000 steps per day is presented. The weight loss system can comprise an effective amount of: an antimicrobial component that includes berberine, cinnamon and curcumin; fish oil; a probiotic component that includes Lactobacillus spp., Bifidobacterium spp., and Streptococcus spp.; an antioxidant, phytochemical component that includes apple extract, grape extract, green tea extract, and olive extract; and a vitamin component that includes vitamins A, B, C, D, and E. The weight loss system can stimulate a weight loss of at least 3% more than if not administered to the subject. Further presented herein is a method of facilitating weight loss in a subject and a method of improving the health of a subject participating in a weight loss program.

Abstract: The present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases. More specifically, the present invention provides a pharmaceutical composition to be used for the treatment or prophylaxis of allergic diseases, which contains a substance that induces selective IgA class switching in B cells. As a substance that induces selective IgA class switching in B cells, a PKC activator can be used. In addition, a composition containing a substance that induces selective IgA class switching in B cells can also be useful as a mucosal adjuvant.

Abstract: The present invention relates to methods and compositions for illuminating, characterizing and demonstrating the uses for microbial and plant interactions, plant nutrient uptake, environmental chemical degradation, petroleum degradation, quality control for seed treatment and fertilizer blends and diagnostics on agricultural applications.

Abstract: It has been discovered that the desert endophytic bacterium SA187 SA187 can provide resistance or tolerance to abiotic stress conditions to seeds or plants. Compositions containing SA187 can be used to enhance plant development and yield under environmental stress conditions.

Abstract: The present invention relates to a method for treating liver steatosis or non-alcoholic fatty liver by using a 2-monoacylglycerol degrading enzyme. More particularly, the present invention provides a method for treating metabolic syndrome such as liver steatosis, non-alcoholic fatty liver, hyperlipidemia, type 2 diabetes, and/or obesity by using a 2-monoacylglycerol degrading enzyme, in which the 2-monoacylglycerol degrading enzyme completely degrades triglyceride into fatty acids and glycerol in a digestive tract such that fat absorption is delayed and blood absorption of triglyceride is decreased, and in which, in a case where monoacylglycerol is degraded by a monoacylglycerol lipase in a digestive tract, although degraded products of the monoacylglycerol are absorbed into digestive epithelial cells, recombination thereof into triglyceride in the digestive epithelial cells is delayed or energy consumption is promoted during this process.

Abstract: The present invention relates to reduction of erythrocyte sedimentation rate in a blood sample. In particular, formulations, compositions, articles of manufacture, kits and methods for reduced erythrocyte sedimentation rate in a blood sample are provided.

Abstract: The present invention provides for a probiotic composition for enhancing a subject's, such as an insect's, resistance to a pesticide comprising: (a) a microorganism capable of expressing one or more enzymes for metabolizing the pesticide, and (b) at least one feed ingredient for a subject. The present invention also provides for a method for enhancing a subject's, such as an insect's, resistance to a pesticide comprising administering to a subject the probiotic composition.

Abstract: The present invention provides a nanoreactor (nano size reaction field) using a polyion complex polymersome and a method for producing the nanoreactor. The present invention provides a polyion complex polymersome encapsulating e.g., an enzyme, in which the enzyme is an enzyme acting on a substance passing through a membrane of the polyion complex polymersome, as a substrate.

Abstract: A fixative for the preservation of organic tissue and cell aggregates, comprising a hydrophilic denaturant for structural change of the molecules of the organic tissue, a lipophobic solvent, in which said denaturant is dissolved, and an amphiphilic infiltration agent which is dissolved in the solvent for dissolving fats on the surface of the biological tissue in order to accelerate a penetration of the denaturant into the biological tissue.

Abstract: A method of producing chemicals includes providing fermentative cells; co-feeding any of galacturonate and galacturonate polymers with carbohydrates to the fermentative cells; and producing a chemical from the fermentative cells. The fermentative cells may include any of Clostridium acetobutylicum and Clostridium saccharoperbutylacetonicum. The carbohydrates may include any of glucose, mannose, galactose, fructose, arabinose, xylose, sucrose, lactose, maltose, cellobiose, and starch. The method may include providing a substantially equal proportion of the any of galacturonate and galacturonate polymers and the carbohydrates for co-feeding to the fermentative cells. The method may include altering a proportion of the any of galacturonate and galacturonate polymers to the carbohydrates. The method may include modulating a production of the chemical by altering the proportion of the any of galacturonate and galacturonate polymers to the carbohydrates. The chemical may include any of acetate and butyrate.

Abstract: A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus Veillonella, genus Faecalibacterium, genus Phascolarctobacteria, genus Oscillospira, genus Ruminococcus, genus Bacteroides, genus Blautia, family Christensenellaceae, genus Dialister, or phylum cyanobacteria.

Abstract: The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers.